Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Interest & Investment Income (2016 - 2025)

Regenxbio has reported Interest & Investment Income over the past 11 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $2.7 million for Q4 2025, down 71.15% from a year ago — trailing twelve months through Dec 2025 was $12.2 million (down 34.62% YoY), and the annual figure for FY2025 was $12.2 million, down 34.62%.
  • Interest & Investment Income for Q4 2025 was $2.7 million at Regenxbio, down from $3.6 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for RGNX hit a ceiling of $9.5 million in Q4 2024 and a floor of $311000.0 in Q4 2021.
  • Median Interest & Investment Income over the past 5 years was $2.4 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Interest & Investment Income: crashed 97.75% in 2021 and later soared 551.45% in 2022.
  • Regenxbio's Interest & Investment Income stood at $311000.0 in 2021, then soared by 551.45% to $2.0 million in 2022, then increased by 16.78% to $2.4 million in 2023, then surged by 302.2% to $9.5 million in 2024, then crashed by 71.15% to $2.7 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.7 million (Q4 2025), $3.6 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.